What Is Leptin? Benefits, Research & Safety
A hormone produced by fat cells that regulates appetite, energy expenditure, and body weight.
Quick Facts
In This Guide
Overview
Discovery & History
Mechanism of Action
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Effective treatment for congenital leptin deficiency (dramatic weight loss)
- 2Approved for metabolic complications of generalised lipodystrophy
- 3Restores menstrual function in leptin-deficient women
- 4Improves insulin sensitivity in lipodystrophy
- 5Reduces triglycerides and hepatic steatosis in lipodystrophy
- 6Research into hypothalamic amenorrhea treatment ongoing
Theoretical Dosing & Protocols
| Theoretical Dosage | Lipodystrophy: weight-based dosing (e.g., 0.06 mg/kg/day, adjusted based on response) |
| Frequency | Once or twice daily subcutaneous injection |
| Duration | Chronic treatment for ongoing indications |
| Notes | Metreleptin is only approved for specific conditions with leptin deficiency or resistance (lipodystrophy). It is NOT effective for common obesity due to leptin resistance. Use requires specialist prescription and monitoring. Off-label use for weight loss is not supported by evidence. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (only approved route)
| Half-Life | Stability |
|---|---|
| Approximately 3-4 hours for recombinant leptin | Requires refrigeration; reconstituted solutions should be used within manufacturer specifications |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions
- Headache
- Hypoglycaemia (especially if on insulin)
- Weight loss (intended effect in appropriate patients)
- Fatigue
Rare Risks & Concerns
- Development of anti-leptin antibodies (can neutralise effect)
- T-cell lymphoma (boxed warning—observed in lipodystrophy patients, unclear if drug-related)
- Severe infections
- Autoimmune disorders
Contraindications
- Patients with obesity not related to leptin deficiency
- Known hypersensitivity to metreleptin
- General obesity (due to lack of efficacy and potential risks)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Metreleptin (Myalepta) available through specialist centres for lipodystrophy. Strict prescribing guidelines apply.
🇪🇺 European Union
EMA approval for generalised lipodystrophy. Requires specialist metabolic centre prescription.
Clinical Studies Summary
Leptin Treatment of Congenital Leptin Deficiency
Landmark studies showing dramatic weight loss and metabolic improvement in rare patients with genetic leptin deficiency.
Metreleptin for Lipodystrophy
Clinical trials supporting FDA approval for metabolic complications of generalised lipodystrophy.
Leptin and Hypothalamic Amenorrhea
Research on leptin replacement in women with exercise-induced or low-weight amenorrhea showing restoration of menstrual function.
Looking for Leptin?
Source research-grade Leptin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreGLP-1
A natural incretin hormone that regulates blood glucose and appetite, the basis for revolutionary diabetes and obesity medications.
Learn moreGhrelin
The 'hunger hormone' that stimulates appetite and growth hormone release, with important roles in metabolism and energy balance.
Learn moreAmylin
A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.
Learn moreSemaglutide
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, representing a breakthrough in metabolic medicine with average weight loss of 15-17% in clinical trials.
Learn more